Core Viewpoint - Morgan Stanley's report indicates that MicroPort Scientific Corporation (02252) has shown stronger-than-expected order trends in the first half of the year, reflecting a structural shift in growth and profitability drivers [1] Financial Performance - The company's revenue increased by 77% year-on-year, while net losses narrowed by 59% [1] - Overseas sales surged by 189%, accounting for 58% of total revenue, highlighting the significance of international business as a core growth engine [1] Future Guidance - Management has set a target for approximately 85% revenue growth for the year and aims to further reduce net losses [1] - The company plans to strictly control capital expenditures between 5 million to 10 million RMB, with a goal of keeping free cash outflow below 200 million RMB [1] Analyst Rating and Price Target - Morgan Stanley raised the target price from HKD 19.1 to HKD 30.9 and upgraded the rating from "Neutral" to "Overweight" based on the company's growth prospects [1]